Provided by Tiger Trade Technology Pte. Ltd.

Tonix Pharmaceuticals

14.18
+0.58504.30%
Volume:468.98K
Turnover:6.56M
Market Cap:243.12M
PE:-1.14
High:14.50
Open:13.68
Low:13.35
Close:13.59
52wk High:31.55
52wk Low:9.40
Shares:17.15M
Float Shares:14.99M
Volume Ratio:0.87
T/O Rate:3.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.4882
EPS(LYR):-14.5713
ROE:-81.82%
ROA:-46.84%
PB:1.09
PE(LYR):-0.97

Loading ...

Tonix Pharma (TNXP) Receives a Buy from Alliance Global Partners

TIPRANKS
·
May 04

Tonix Pharmaceuticals initiated with a Buy at TD Cowen

TIPRANKS
·
May 04

Tonix Q1 net loss widens to $40.8 million; net revenue rises to $6.9 million

Reuters
·
May 02

Tonix plans adaptive Phase 2 field trial of TNX-4800 for Lyme prevention

Reuters
·
Apr 29

Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026

GlobeNewswire
·
Apr 23

Tonix publishes Day 20 steady-state PK study of TONMYA in clinical journal

Reuters
·
Apr 15

Tonix publishes investor deck highlighting TONMYA fibromyalgia launch, reports USD 208 million cash

Reuters
·
Apr 08

Analysts Offer Insights on Healthcare Companies: Privia Health Group (PRVA), Nuvalent (NUVL) and Tonix Pharma (TNXP)

TIPRANKS
·
Apr 06

Tonix CEO Seth Lederman buys TNXP shares worth $0.1 million

Reuters
·
Apr 01

Tonix publishes investor presentation highlighting TONMYA fibromyalgia drug launch progress

Reuters
·
Apr 01

Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026

GlobeNewswire
·
Mar 31

Tonix Pharmaceuticals Stock Hits New 52-Week Low: What's Driving The Action?

Benzinga
·
Mar 30

Tonix Pharmaceuticals dosed first participant in Phase 1 TNX-1900 intranasal oxytocin study; trial measures trigeminal neurovascular reactivity in healthy female volunteers

Reuters
·
Mar 26

Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of Tnx-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain

THOMSON REUTERS
·
Mar 26

Tonix publishes investor presentation on TONMYA fibromyalgia launch and pipeline plans

Reuters
·
Mar 25

BRIEF-Tonix Pharmaceuticals Announces Presentations At World Vaccine Congress Washington 2026

Reuters
·
Mar 24

Tonix Pharmaceuticals Holding Corp. Announces Annual Shareholder Meeting

Reuters
·
Mar 21

Tonix Pharmaceuticals CEO Seth Lederman to present at BIO-Europe Spring 2026

Reuters
·
Mar 19

Tonix Pharmaceuticals replaces EisnerAmper with PwC as independent auditor

Reuters
·
Mar 18

Tonix Pharmaceuticals to present oral and two poster sessions at AACR Annual Meeting 2026

Reuters
·
Mar 18